Jan 05,2023

Mental Health App Woebot Passes ORCHA's Rigorous New Digital Health Assessment Framework

Woebot, a mental health app from Woebot Health that provides personal and immediate support to people who are experiencing symptoms of anxiety and depression, has passed the rigorous new Digital Health Assessment Framework (DHAF) that aims to enhance health application standards in the United States. The open framework includes components to assess privacy and security, clinical assurance and safety, and usability, and was crafted to support U.S.-specific guidelines, regulations and best practices for digital health technologies.

PRODUCT

#chatbot

#cbt

View Analyst & Ambassador Comments
Go to original news
May 03,2023

Woebot Health Named "Best Overall Mental Health Solution" in 2023 MedTech Breakthrough Awards Program

Woebot Health today announced that it has been selected as winner of the “Best Overall Mental Health Solution” award in the 7th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.

PRODUCT

#chatbot

View Analyst & Ambassador Comments
Go to original news
Jun 08,2023 TOP STORY

Kaia Health Launches Industry's First Digital Care Assistant Giving Patients a Companion and Guide to Enhance Their Physical Therapy Experience

Kaia Health, the digital therapeutics company with more than 650,000 users today announced the launch of Angela, a HIPAA-compliant, AI-powered voice-based digital care assistant, companion, and guide. Angela provides patients with the personalized support they need at the time and place that is most convenient for them, creating a richer, more human-like experience. If the patient is having any issues - such as pain during a particular exercise - Angela works to understand all the details and summarizes them for the care team so that they can respond directly with the help that is needed. She also provides real-time encouragement, support, and motivation.

PRODUCT

#chatbot

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 13,2023

Q&A: Integrating digital health apps into clinical care with Trina Histon

Trina Histon, vice president of clinical product strategy at Woebot Health, discusses incorporating digital health tools into the provider workflow. Histon's new role as vice president of clinical product strategy will focus on integrating Woebot into clinical care. She previously spent several years at Kaiser developing a process to get digital mental health apps from clinicians into patients' hands.

#chatbot

View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Massive Bio Launches Revolutionary ChatGPT-Powered Chatbot Platform at ASCO 2023 to Simplify and Expand Access to Oncology Clinical Trials

Massive Bio, a world-renowned provider of personalized oncology solutions, is set to showcase its GPT4 AI chatbots – AskFiona AI and DrArturo AI at ASCO 2023. AskFiona AI, an advanced AI chatbot, serves as a comprehensive guide through the intricacies of clinical trials. Adding depth to this patient-focused approach, DrArturo AI functions as an invaluable virtual oncology tool for providers including oncologists and hematologists. Offering detailed, personalized information about specific clinical trials, including treatment details and insurance acceptance, this AI tool aims to ensure patients, their families, and physicians are equipped with all necessary information to make informed decisions.

PRODUCT

#chatbot

View Analyst & Ambassador Comments
Go to original news
Jun 03,2023 TOP STORY

Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, announced a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care. Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI’s active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine. By leveraging sophisticated algorithms and comprehensive diagnostic information, Massive Bio will empower patients and ordering physicians at TOI with clinical decision-support and clinical trial matching services. Furthermore, this collaboration will expand the scope of cancer research through Massive Bio’s recent ChatGPT-powered chatbots for oncology research release during ASCO 2023.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#chatbot

View Analyst & Ambassador Comments
Go to original news
May 23,2023

Revolutionary ChatGPT-Powered Chatbot Platform at ASCO 2023

Massive Bio, a leading provider of personalized oncology solutions, will be participating in the prestigious American Society of Clinical Oncology (ASCO) annual meeting from June 2nd to June 6th. The event serves as a platform for sharing groundbreaking advancements in cancer care, and Massive Bio is excited to unveil its innovative ChatGPT-powered chatbot platform featuring AskFiona AI and DrArturo AI. With AskFiona AI as the initial point of contact, patients can receive comprehensive insights into clinical trials, understanding their purpose and assessing eligibility. The platform seamlessly escalates patients to DrArturo AI, providing tailored information about specific clinical trials, including treatment details, schedules, nearest treatment facilities, and more.

PRODUCT

#chatbot

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 14,2023

Dave, the World’s First Real-time Conversational AI Oncology Mentor

Belong.Life, a leading global provider of high-engagement patient communities and care platforms, today announced the launch of Dave, the world’s first conversational AI oncology mentor for cancer patients. With the mission of improving access to quality cancer care for patients worldwide, Dave brings a new level of support to cancer patients and their families. Dave is designed to engage and continuously educate, support and guide cancer patients and caregivers on their clinical journey, providing support and personalized information. Conversational AI platform created and trained using deep learning on billions of unique data points and anonymized real world patient journey information accumulated over seven years on Belong’s platform.

PRODUCT

#mobile app

#chatbot

View Analyst & Ambassador Comments
Go to original news
Apr 10,2023

ChatGPT has Potential to Help Cirrhosis, Liver Cancer Patients

A new study by Cedars-Sinai investigators describes how ChatGPT, an artificial intelligence (AI) chatbot, may help improve health outcomes for patients with cirrhosis and liver cancer by providing easy-to-understand information about basic knowledge, lifestyle and treatments for these conditions. The findings, published in the peer-reviewed journal Clinical and Molecular Hepatology, highlights the AI system’s potential to play a role in clinical practice. Patients diagnosed with liver cancer and cirrhosis, an end-stage liver disease that is also a major risk factor for the most common form of liver cancer, often require extensive treatment that can be complex and challenging to manage. Personalized education AI models could help increase patient knowledge and education, noted Alexander Kuo, MD, medical director of Liver Transplantation Medicine at Cedars-Sinai and co-corresponding author of the study.

CLINICAL STUDY

#ai/software

#chatbot

View Analyst & Ambassador Comments
Go to original news
Mar 07,2023

Using ChatGPT to write patient clinic letters

AI, like ChatGPT, has the potential to produce high quality clinical letters that are comprehendible by patients while improving efficiency, consistency, accuracy, patient satisfaction, and deliver cost savings to a health-care system. In this Comment researchers describe the early adoption and evaluation of ChatGPT-generated clinical letters to patients with limited clinical input. They created a series of different clinical communication scenarios that covered the remit of a clinicians' skin cancer practice. 38 hypothetical clinical scenarios were created, seven of which pertained to BCC, 11 to squamous cell carcinoma (SCC), and 20 to malignant melanoma. Overall, the readability scores suggest that the text might be suitable for a varying reading ability, and the mean readability age for the generated letters was at a USA ninth grade (aged 14–15 years) and considered by the US Department of Health and Human Services as average difficulty.

CLINICAL STUDY

#ai/software

#chatbot

View Analyst & Ambassador Comments
Go to original news
Subscribe to CHATBOT